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hese past two decades,research on the molecu-
lar mechanisms mediating the effects of pharmacologi-
cal substances has been marked by enormous progress.
The first important steps were the purification and iso-
lation of receptor proteins,the existence of which had
until then been hypothesized on the basis of their char-
acteristic pharmacological effects.The next major steps
were the cloning of the genes encoding these proteins
1
and the discovery of a much greater multiplicity at the
DNA level underlying the pharmacologically defined
effects;many more receptor subtypes were found to exist
at the DNA level than had originally been proposed on
the basis of pharmacological classification.
2 The avail-
ability of the gene sequences provided the basis for pro-
tein structural models.For instance,the gene family of G
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T
The analysis of genetic variation in candidate genes is an issue of central importance in pharmacogenomics. The spe-
cific approaches taken will have a critical impact on the successful identification of disease genes, the molecular cor-
relates of drug response, and the establishment of meaningful relationships between genetic variants and phenotypes
of biomedical and pharmaceutical importance in general. Against a historical background, this article distinguishes
different approaches to candidate gene analysis, reflecting different stages in human genome research. Only recently
has it become feasible to analyze genetic variation systematically at the ultimate level of resolution, ie, the DNA
sequence. In this context, the importance of haplotype-based approaches to candidate gene analysis has at last been
recognized; the determination of the specific combinations of variants for each of the two sequences of a gene defined
as a haplotype is essential. An up-to-date summary of such maximum resolution data on the amount, nature, and struc-
ture of genetic variation in candidate genes will be given. These data demonstrate abundant gene sequence and hap-
lotype diversity. Numerous individually different forms of a gene may exist. This presents major challenges to the analy-
sis of relationships between genetic variation, gene function, and phenotype. First solutions seem within reach. The
implications of naturally occurring variation for pharmacogenomics and “personalized” medicine are now evident.
Future approaches to the identification, evaluation, and prioritization of drug targets, the optimization of clinical tri-
als, and the development of efficient therapies must be based on in-depth knowledge of candidate gene variation as
an essential prerequisite.
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includes the majority of pharmacologically defined
receptors
2,3 and represents more than 50% of all drug tar-
gets
4—features the characteristic structural motif of
seven transmembrane-spanning domains connected by
intracellular and extracellular loops and terminal regions
exposed at both faces of the membrane.
3The structural
model allowed investigation of the molecular basis of
receptor functions,such as ligand binding,signal trans-
duction via G protein–coupling, and regulation (for
example,of desensitization).
5
First analyses of sequence–structure–function relation-
ships were performed.In order to correlate specific com-
ponents of receptor function with specific amino acids,
the effects of mutations introduced into the “wild type”
sequence by in vitro site-directed mutagenesis were
examined.It was demonstrated that DNA sequence dif-
ferences caused differences in receptor function.
Mutations were shown (i) to significantly affect the abil-
ity of the receptor to bind ligands with a characteristic
specificity and affinity;(ii) to activate characteristic and
specific effectors;and (iii) to undergo functional regula-
tion.
6At this stage,mutations were conceived primarily
as the result of experimental intervention and as an
important tool for analyzing the functional content of
DNA sequence information.The possibility that muta-
tions might occur as natural phenomena that confer a
spectrum of natural functional variations was simply not
part of the picture or even an acknowledged hypothesis.
For as long as one could think of, pharmacological
effects were conceived as specific,uniform values,which
were defined by a mean value (the average of all indi-
vidual values) and a standard error (an indication of the
extent of deviation of the individual values from the
mean,ie,the usual scattering of these values).Such vari-
ability was supposed to reflect deviation from the true
value as a result of confounding parameters,which intro-
duced the errors in the process of measurement.At its
extreme,the mean value described an effect that did not
apply to any of the individuals who participated in the
experiment.
A gradual change in concept to the conscious notion of
individual variability at the pharmacological,clinical,and
molecular level,and the acceptance of variation as the
frame of reference and object of research did not emerge
until the very early days of the Human Genome Project.
On the basis of vision more than fact,it was hypothesized
that differences in DNA sequence—the most basic level
of molecular information—were related to individual
genetic differences in drug response.
6,7The hypothesis of
a biochemical individuality of man and its relationship to
pharmacogenetic phenomena had already been raised in
the early 1900s
8 and first observations of individual dif-
ferences in the response to the same drug had been made
by Pythagoras as early as the fifth century BC.
9 However,
these observations were generally considered exceptions
from the rule.Only in the past few years,has the picture
substantiated that variations may frequently occur natu-
rally and a broad spectrum of normal variation,reflect-
ing naturally diverse individual gene and genome
sequences,may exist,giving rise to subtle functional dif-
ferences.This change in concepts marks the beginning of
the end of Mendel’s world,
10 which was filled with rare
mutations that caused discrete protein effects and gross,
visible phenotypic effects.
Progress in human genome research 
transforms genetic variation into 
a central research theme
Major developments in the Human Genome Project have
catalyzed a dramatic change in picture,transforming the
analysis of genetic variation and its implications for dis-
ease causation and individually different drug response
into a major research theme. Pharmacogenomics, the
vision of a “personalized”medicine and the development
of prescriptions with a personal touch, has become the
focus of attention and a widely discussed topic.
11-14 Such
progress was in particular spurred by the development of
cloning and high-throughput sequencing technologies,
15
the availability of a draft sequence of the human
State of the art
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Selected abbreviations and acronyms
DGGE  denaturing gradient gel electrophoresis
DHPLC denaturing high-performance liquid 
chromatography
EST expressed sequence tag
LD linkage disequilibrium
RFLP restriction fragment length polymorphism
SNP single nucleotide polymorphism
SSCP single-stranded conformation polymorphism
STR short tandem repeat
STS sequence-tagged site
UTR untranslated region
VDA variant detection array
VNTR variable number of tandem repeatsgenome,
16,17 and consequently,access to all human genes
and their regulators,transcripts,and proteins as the basis
for disease gene and drug target discovery.With defined
reference sequences of genes and genomes, sequence
comparisons within and between species became feasible
and, consequently, the identification of differences in
DNA sequence, so-called single nucleotide polymor-
phisms (SNPs).
18 For the first time,human genome varia-
tion data were generated on a large scale,resulting in the
establishment of SNP maps
19 and public variation data-
bases.Thus,it was for the first time possible to study the
amount,nature,and structure of human genetic variation
on a large scale.
20-23 For this purpose,different approaches
were taken,ie,completely different approaches to reso-
lution, which led to completely different pictures of
genetic variation.
In the first series of studies,the structure of genetic vari-
ation (specifically the pattern and extent of linkage dise-
quilibrium [LD] between SNPs) was assessed on a
genome-wide scale.Common SNPs,with frequencies of
the minor allele >5% to >30%,were randomly generated
or extracted from databases at distances of 1.3 to 15 kb,
and genotyped in limited numbers of individuals.As a
result,SNPs were found to cooccur,ie,exist in blocks of
strong LD,within genomic regions that extended up to
about 60 to 100 kb in populations of European descent.
20-23
These specific combinations of closely linked SNP alleles
(haplotypes) were separated by regions of recombination,
indicating a haplotype block structure of the human
genome.
20-23 Because the strong LD between SNPs
appeared to result in a striking lack of genetic diversity,
only a limited number of haplotypes, two to five per
block,were observed,accounting for 75% to 98% of all
chromosomes.
At the other end of the extreme, a number of studies
were performed to systematically analyze genetic varia-
tion at the ultimate level of resolution, ie, the DNA
sequence. Defined candidate genes, DNA segments of
several kilobases, were comparatively sequenced in
larger numbers of individuals.
24-34 These first studies
reflect as closely as possible the molecular truth.They
revealed abundant gene sequence diversity,
31,35 about one
SNP every 160 to 180 bp,and revised the classical mea-
sures of genetic variability.
35-37 They also demonstrated
unpredictable patterns of LD even within short distances
of several hundred basepairs,much higher numbers of
haplotypes,sometimes exceeding a hundred,and much
more complex haplotype structures
38 than suggested by
the previous studies.To conclude,the higher the resolu-
tion,the higher the variability,and the more complex the
picture.
39 It is now important to develop a critical aware-
ness for such differences in resolution.It is important to
know where one stands relative to the virtual optimum,
maximum resolution,and to be able to put results into
perspective. This is particularly important in order to
make inferences on the validity of genotype–phenotype
relationships as they have been established in the stud-
ies of interest.
Comprehensive knowledge on amount,
nature, and structure of genetic variation: 
an essential prerequisite
This article first provides an overview of methods and
approaches to the analysis of genetic variation as they
have developed over time,reflecting a gradual transition
from the indirect,random assessment of variations basi-
cally guided by chance,to the increasingly systematic and
complete resolution of defined candidate gene regions.
The emphasis on the historical dimension should facili-
tate the distinction of different,and currently coexisting,
approaches. Second, the importance of a whole gene
sequence–based,systematic analysis of genetic variation
and its underlying haplotype structures will be outlined.
Third,a state-of-the-art summary of present data describ-
ing genetic variation in candidate genes—its amount,
nature,and structure at the highest possible level of res-
olution to date will be given.These data reveal an abun-
dant sequence diversity as well as complex haplotype
structures.This demonstrates at the experimental level
that it is essential to resolve genetic variation and its
underlying structures as systematically as possible, in
order to design successful association studies and estab-
lish meaningful relationships with gene function and phe-
notype.The implications of given natural variability for
pharmacogenomics and a personalized medicine will
then be summarized in the following section.Finally,the
tremendous challenges posed by both variability and the
complex nature of pharmacogenetically relevant traits
will be addressed and first solutions and future perspec-
tives outlined.Because this article addresses basic issues
regarding the nature and interpretation of genetic vari-
ability in candidate genes as the central unit of analysis
in pharmacogenomics, it complements the articles by
Ackenheil and Weber
40 and Morris-Rosendahl and
Fiebich
41 in this volume.
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7Approaches to the analysis of genetic varia-
tion and genotype–phenotype relationships
It is essential to keep the historical dimension in mind,
which has shaped approaches to the analysis of genetic
variation in disease and,importantly,the concepts about
how to establish links between genotype and phenotype.
This will allow putting past and present approaches and
the results they generated into perspective.
39 For most of
the time,a comprehensive analysis of the entire variation
given in candidate genes has been neither feasible nor
practicable,nor efficient.
Even though the sequences of numerous candidate genes
of interest had become available in the late 1980s, the
first systematic candidate gene analyses were not per-
formed until the late 1990s.The methods at hand were
indirect,ie,the variations were detected without directly
analyzing DNA sequence.The variations were selected
randomly,ie,without emphasis on specific functionally
relevant gene regions.They were selected out of context,
ie,given variation in the other parts of the gene were not
issues of primary relevance.What was feasible and what
mattered was to be able to detect any polymorphism(s)
at all in and around the gene to be able to test the candi-
date gene hypothesis.The limited availability of tech-
nologies to access genetic variation restricted the num-
ber of detectable polymorphisms and determined the
type of variants identified.What counted were the ease
and robustness of typing and the numbers and frequen-
cies (informativeness) of the alleles in order to be able to
perform informative association studies.For years,the
variable sites utilized for such studies were largely rep-
resented by restriction fragment length polymorphisms
(RFLPs), different kinds of repeat markers such as
microsatellites,short tandem repeat (STR),or variable
number of tandem repeats (VNTR) markers.The pres-
ence of variation within the restriction site of an enzyme
or the presence of a repeat marker anywhere in the gene
region were chance events that illustrate the randomness
of these approaches.
Later, the analysis of SNPs, the most frequent type of
variation in the human genome, gained center stage.
These were,in the early to mid 1990s,mostly identified
by application of polymerase chain reaction (PCR)–
based mutation scanning methods, such as single-
stranded conformation polymorphism (SSCP) detection
or denaturing gradient gel electrophoresis (DGGE),
which were supposed to detect 80% to 95% of all vari-
ants.In the optimal case,they were found to cause a func-
tionally significant amino acid exchange, which would
allow the direct testing of potentially causative alleles.
18
In the late 1990s,when the Human Genome Project was
in progress,SNPs were generated randomly at large scale
in vitro and in silico.
19,42-44 They were identified by (i)
sequencing sequence-tagged sites (STSs) from random
genomic sequence and expressed sequence tags (ESTs)
primarily representing untranslated regions of genes
44;
(ii) shotgun sequencing of genomic fragments
42;and (iii)
analysis of clone overlaps by the International Human
Genome Sequencing Consortium.
16,42Any discrepancies
in sequences were considered potential SNPs.Only about
5% of the SNPs in the SNP map were discovered in stud-
ies that analyzed genes as compared to randomly gener-
ated genomic fragments.
19,45 Comparison of SNPs that
were detected by systematically scanning
46 or resequenc-
ing a substantial number of candidate genes,eg,a total of
318 genes in the largest study performed to date,
33
showed that public SNP databases contained only 2% to
25% of those genic SNPs.
Given this historical background,the approach taken in
the majority of studies was to evaluate single polymor-
phisms or SNPs in and around the gene,one at a time,for
association with the disease.
20,39,47 Importantly,polymor-
phisms were conceived as genetic markers that would
allow inference of an unobserved causative allele,
18,48
which could not have been identified due to the
restricted analysis range or insufficient depth of analysis.
In this approach,all polymorphisms,SNPs,or any other
of the classes of polymorphisms mentioned above,were
conceptually equivalent, irrespective of their specific
functional significance.
48
Thus,the major rationale underlying all genetic mapping
by association approaches is that a marker allele exists in
strong LD with the unobserved causative allele,which
indicates the presence of the disease allele.
48This ratio-
nale essentially underlies all present approaches to asso-
ciation analysis,given that information on genetic vari-
ation in genes and genomes remains widely incomplete
and relies on subset approaches.In order to enhance the
heterozygosity—and hence informativeness of the mark-
ers defining a gene region—and have greater power to
map unobserved causative variants by LD,
48 several poly-
morphisms (of any class) were combined to construct
haplotypes,which are defined in this context as the spe-
cific combinations of—desirably independent—alleles at
two or more polymorphic sites on an individual chromo-
State of the art
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some.
39Again,the combination of markers that was used
to construct haplotypes was primarily selected on the
basis of availability,practicality,and heterozygosity,ie,the
result of random screening procedures. An important
preassumption implied in the use of single or several
markers was that these would represent underlying LD
structures, even at distances of several kilobases, and
hence be appropriate to capture the disease variant.
To conclude,previous approaches to the analysis of can-
didate genes have not been based on systematic assess-
ment of given candidate gene variation.Consequently,
the variants chosen for analysis actually represented ran-
domly selected variants and,obviously,only a subset of
the naturally existing variants.On the basis of such a tra-
ditional single SNP approach,numerous association stud-
ies have been performed,particularly in the field of psy-
chiatric genetics. One major characteristic of these
studies is that they generated a vast body of controver-
sial results;a typical example is the story of the dopamine
D2 receptor gene and alcoholism.
49
In the late 1990s, it became feasible to systematically
evaluate genetic variation at the ultimate level of reso-
lution,ie,the DNA sequence,as demonstrated in a series
of comparative sequencing studies.
24,25,27-33These studies
revealed presence of abundant sequence diversity and
far more complex underlying LD structures than had
previously been anticipated.
24,25,27,29,31-33,38,50This substantially
changed the view of the amount,pattern,and structure
of genetic variability in genes and genomes.
35
Evidence of abundant sequence diversity began to raise
doubts about the validity of traditional single SNP
approaches.
30,38Apart from theoretical considerations,
29 it
was shown that multiple variants can exist within genes
and that the combinations of variants on each of the two
copies of a gene (haplotypes) should become the focus of
analysis.First,systematic comparative sequencing studies
demonstrated that the analysis of haplotypes defined by
the grouping and interaction of several variants rather
than any individual SNP were correlated with complex
phenotypes, such as drug response and common dis-
ease.
24,29,51 Finally,when evidence for a haplotype structure
of the human genome was obtained,it was explicitly rec-
ognized that single SNP-based candidate gene approaches
may be statistically weak and have no clear end point;
true associations may be missed because of the incom-
plete information provided by individual SNPs;negative
results exclude particular SNPs as playing a role,but can-
not exclude a gene.
20This was the beginning of the end of
single SNP approaches;haplotype-based approaches to
candidate gene analysis and disease gene discovery had
at last become the state of the art.
39
The systematic analysis of candidate genes: 
a necessary precondition to establish links 
to gene function, disease, and drug response
The importance of haplotypes: context matters
Only the entire gene sequence,given in its individually
variable forms,can be correlated with the function,reg-
ulation, and expression of the protein and, ultimately,
phenotype.“Since it is the entire gene and its encoded
protein that act as the units of function potentially affect-
ing a phenotype (and ultimately allow initial conclusions
on disease mechanisms), we must analyze the entire
sequences of the individual genes including their regula-
tory and intronic regions. It is therefore essential in
diploid organisms (such as humans) to determine the
specific combinations of all given gene sequence variants
for each of the two chromosomes defined here as haplo-
types.”
29Thus,a systematic approach to candidate gene
analysis necessarily implies the determination of the hap-
lotype pairs underlying each individual genotype.In this
context, it is important to note that this definition of
gene-based functional haplotypes should be distin-
guished from other haplotype categories
39 (which,in part,
have also been utilized above),which generally refer to
combinations of SNPs or any markers that may be
located throughout genes,
48 extend over any chromoso-
mal regions, or identify (in the most recent definition)
sets of markers in LD within a block of chromosomal
sequence (haplotype blocks).
20,39 It is also important to
note that current (mixed diploid) direct sequencing
methods allow determination of genotype,but not phase,
ie, the assignment of the SNPs to one of the two chro-
mosomes.
The correct determination of the molecular haplotypes
underlying each genotype in a given sample is essential
to make conclusions about the functionality of both
forms of the gene,and establish relationships between
gene variation and gene function in general.
52-54 For
instance,mutations that reside on the same chromosome
(cis) may leave the function of the other gene copy intact.
If, however, the two mutations reside on two different
chromosomes (trans), they may inactivate both gene
copies (Figure 1).
53,55State of the art
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This example also demonstrates that the selection of sin-
gle SNPs out of context would not allow distinction
between different underlying haplotype pairs and,ulti-
mately, between high- and low-risk alleles.The impor-
tance of analyzing genetic variation in candidate genes
systematically and comprehensively is further demon-
strated by the fact that SNPs located in one segment of
the gene may,in three-dimensional (3D) space and with
the DNA structural model in mind,interact with SNPs
located in quite distant segments of the gene;distance in
terms of linear sequence may be equivalent to proximity
in space.In light of the sequence–structure–function rela-
tionship,all variants will have to be identified since any
variant may have functional impact,whether it is consid-
ered essential or redundant with regard to indication of
the underlying LD structure of the gene (its genetic
marker function).In light of a sequence–structure–func-
tion paradigm,the haplotype as defined above represents
the immediate correlate for the individual,functional,or
dysfunctional protein(s) it encodes,as well as related reg-
ulatory sequences.These gene-based functional haplo-
types are of immediate relevance for pharmacogenomics:
as potential disease gene correlates and/or drug targets;
and as the basis for drug target characterization,evalu-
ation,prioritization,and diagnostic test development.
The importance of obtaining complete sequence informa-
tion on each individual form of the gene is also demon-
strated by the example of the human β2-adrenergic recep-
tor gene (Figure 2).
55,56 This gene, the product of which
represents a key component of the central and peripheral
autonomous nervous systems,is an important candidate
for a spectrum of diseases including neuropsychiatric and
cardiovascular disorders.It is also the target for most com-
monly prescribed drugs.
6 Comparative sequence analysis
of the gene including its regulatory and coding sequences
in several hundred individuals resulted in the discovery of
a total of 15 variants,
55 four of which induced an amino
acid mutation and were each shown to be functionally sig-
nificant in vitro.
57-59 In addition,a number of variants were
identified in the 5' regulatory region.In a preliminary case-
control study,individuals who carried a specific combina-
tion of seven variants (haplotype) (blue in Figure 2) were
significantly more frequently carrying a predisposition to
essential hypertension.
55This potential risk profile included
three SNPs in the 5' regulatory region,and one SNP in the
5' untranslated region (5'UTR) at position –20,and three
Figure 1. Haplotype pairs of two individuals for a gene bearing multiple single nucleotide polymorphisms (SNPs). In this case, the phase of the coding
SNPs determines the genotype. Even though the two individuals A and B are both heterozygous at the variable site positions 2 and 4, indi-
vidual B expresses the gene correctly and individual A does not. Typical single SNP scoring methods would fail to distinguish between the two
individuals, specifically between the two haplotype pairs. It is important to note that current (mixed diploid) direct sequencing methods allow
determination of genotype, but not differentiation of phase, ie, the specific location of each SNP on one of the two chromosomes.
Reproduced from reference 55: Hoehe MR, Timmermann B, Lehrach H. Haplotypes and the systematic analysis of genetic variation: disease genes, drug targets
and pharmacogenomics [in German]. Biospektrum. 2002;8:478-485. Copyright © 2002, Elsevier. 
Haplotype 1
Haplotype 2
Genotype
AB
Nonfunctional Functional
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amino acid mutations in the leader peptide (-47) and
amino terminal of the receptor protein (46 and 79).
The variant at position 46 relative to the translation ini-
tiation site induces a functionally significant Arg>Gly
exchange
60 and was the most frequently used variant in
association studies;the combination of the three muta-
tions at positions -47,46,and 79 were used in some asso-
ciation studies.
61 Neither of these were found to distin-
guish between high- and no-risk alleles. The last four
variants (marked in gray) had no impact statistically,
which beautifully reflects biology:these variants affected
the third base and were silent mutations.
55 Moreover,this
example illustrates that complete sequence analysis is
necessary to focus subsequent functional experiments on
all variants of potential functional significance.Of those
seven variants in LD,one,several,or all variants in inter-
action may contribute to functional differences.Finally,
this example demonstrates the complexity of functional
annotation, given that regulatory and coding variants
occur in combinations.
Gene-based functional haplotypes versus gene-based
complex genetic markers
The definition of a gene-based functional haplotype that
requires complete DNA sequence information in all indi-
viduals is,admittedly,somewhat futuristic at this stage of
human genome research.In many cases,reality may allow
different stages of approximation only.In this regard,the
recently performed comparative gene sequencing studies
24-
26,28-31,33 mark major progress,because their approach to hap-
lotype-based candidate gene analysis is significantly more
systematic and comprehensive than the single SNP or
combination-of-marker approaches used earlier.They also
reflect different stages of approximation to completeness
at an early stage.Sequencing at this stage is still too labor-
and cost-intensive.It is generally not feasible to sequence
all functionally relevant regions of the entire gene (even if
they were all known) in every member of a defined pop-
ulation in order to identify all given variants and their fre-
quencies.
Just to give some impression of the scale of the under-
taking:in order to systematically analyze genetic varia-
tion in a typical G protein–coupled receptor gene includ-
ing regulatory, exonic and intronic sequences
(exon-intron boundaries) in 250 cases and controls,about
1.7 finished megabases (ie, about twice the amount of
raw sequence data to obtain maximum accuracy) need to
be generated,
29 comparable to the size of a bacterial
genome.For completeness of genomic organization,we
should refer to examples that have demonstrated, for
instance,a disease-related regulatory variant about 14 kb
5' upstream of the translation initiation codon or regula-
tory elements in intronic sequences of extensive lengths.
39
Figure 2. Haplotypes of the human β2-adrenergic receptor gene and identification of genetic risk profiles. This figure represents, from left to right, the
specific alleles at each of 11 variable positions (relative to the translation initiation site) in this gene for a subgroup of nine individuals from
the Bergen Blood Pressure Study.
55,56 1: Identical with reference sequence; 2: Different from reference sequence. The individual haplotypes are
given by these specific combinations of 11 alleles as they occur throughout the gene. The three individuals at the top, who are genetically
predisposed to essential hypertension, show potential risk haplotypes, which have in common a specific combination (“pattern”) of alleles at
the first seven positions (marked in blue). This also demonstrates that the most frequently analyzed variant at position 46 (Arg>Gly) and the
combination of the three in vitro functionally significant receptor mutations at positions -47, 46, and 79 are both insufficient to distinguish
individuals at risk. 
Modified from reference 55: Hoehe MR, Timmermann B, Lehrach H. Haplotypes and the systematic analysis of genetic variation: disease genes, drug targets and
pharmacogenomics [in German]. Biospektrum. 2002;8:478-485. Copyright © 2002, Elsevier. 
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IndividualThus,functionally important regions of the gene can at
this stage be included in as representative a way as pos-
sible.Present approaches may still miss what we term the
causative variant(s).
Thus,in practice,we are still dealing (at a comparatively
advanced level) with marker or subset approaches,where
identified variants represent only a selection of all natu-
rally existing variants.Against this background,the gene-
based haplotypes will be categorized as complex genetic
markers.
39A critical question is then whether the subsets
of variation extracted do in fact validly represent given LD
and haplotype structures of a gene.In this case,the result-
ing gene-based haplotypes have been shown to be supe-
rior as markers in comparison to any single SNP,because
they contain more information (heterozygosity) than any
of the individual markers,or SNPs that comprise them.
33,48
Multiple correlations with neighboring, or embedded,
unobserved variants may be possible. Thus, a multisite
gene-based haplotype (higher-order marker) will have
greater power than any individual SNP to detect an unob-
served—but evolutionarily linked—variable causative
site.
48 Such haplotype signatures may,moreover,have sig-
nificantly greater power to predict disease risk and drug
response than any individual SNP within a gene.
24,29,48,51,62 In
the overall process of disease gene identification,it merits
serious consideration to restrict investigations in the first
pass to haplotype marker screening,the apparently less
investment-intensive marker approach.
It should nevertheless be emphasized that if an association
is found, the ultimate challenge to generate complete
sequence information will remain.Subsequent in-depth
comparative sequence analysis of entire gene sequences
in all patients and controls will be indispensable to search
for the presence—or exclude it—of any yet unidentified
variant(s) in LD and extract the subset of all variants in
LD.These have genetically equivalent properties
63 and are
supposed to contain a subset of variants that will be bio-
logically significant.As illustrated by the example of the
human β2-adrenergic receptor gene,these comprehensive
analyses may often not directly result in the identification
of the causative variant(s),but may help locate the region
of interest.
32The function of specific nucleotide sites will
have to be assigned in subsequent functional studies in
vitro and in vivo;one,several,or all of the variants in LD
may be functionally significant and interact.Any genetic
analyses can at best result in testable biological hypothe-
ses on the molecular causes of gene dysfunction.The true
challenges remain biological after all.
Finally,there is yet another motivation for the systematic
analysis of complete candidate gene sequences:we may
have to allow—free of preassumptions—for any scenario
of genetic variation predisposing to disease and individ-
ually different drug response.The spectrum of polymor-
phic profiles may include any variant,or combinations of
variants (patterns),that may interact to determine those
functional variations that are related to phenotypic vari-
ation.Common variants may play a role,rare mutations
may add up,and variants may occur in similar or differ-
ent haplotype frames.
29 In the light of a functional hap-
lotype approach, which ultimately establishes the link
between haplotypes,protein structure,function,and dys-
function,each haplotype matters.Rare ones will have to
be included,because they may well add up to a signifi-
cant fraction of the same (similar) protein isoform,
25 gen-
erally confer functional similarity,or share some common
pattern.
29
State of the art: 
genetic variation in candidate genes
Overview of comparative sequencing and variation
scanning studies
Complete sequence data from a number of nuclear loci
first became available in 1997,
27 providing gradually more
comprehensive information on given DNA sequence vari-
ation within defined segments of DNA.This allows a pre-
liminary synthesis of the amount,nature,and organization
of DNA sequence variation as given at the ultimate level
of resolution.
24This also allows an insight into gene-based
haplotype structures and their complexity at the DNA
sequence level.Altogether,about 20 comparative sequenc-
ing studies have been performed,
24-34,39 which have (i)
explicitly addressed genetic variation in defined candidate
genes;(ii) analyzed most,or substantial parts,of the entire
gene; and (iii) determined in addition the structure of
genetic variation,ie,the gene-based haplotypes,by appli-
cation of molecular genetic and/or in silico methods,
and/or inclusion of family information.These studies have
described interindividual DNA sequence variation in a
total of 331 genes;of those,13 studies have focused on one
candidate gene each,such as the β-globin gene,
27 lipopro-
tein lipase (LPL),
31 melanocortin 1 receptor (MC1R),
64
pyruvate dehydrogenase A1 (PDHA1),
28 angiotensin-con-
verting enzyme (ACE),
32 β2-adrenergic receptor
(ADRB2),
24 µ-opioid receptor (OPRM1),
29 apolipoprotein
State of the art
12E (APOE),
25,30 caspase recruitment domain-containing
protein 15 (NOD2 or  CARD15, respectively),
65-67
monoamine oxidase A (MAO-A)
26 genes, and the
hemochromatosis locus (HFE).
34Two studies have ana-
lyzed three genes each.
68 Specifically,CAPN10,GPR35,
and RNPEPL1
69 were resequenced as an integral part of
a general disease gene cloning procedure.In the currently
most comprehensive study,a total of 313 genes including
a number of G protein–coupled receptor genes,were sys-
tematically resequenced.
33 In some of these studies 5' reg-
ulatory, 3', exonic, and intronic regions were exam-
ined
24,25,27,29,30,32,33;while others addressed exonic and intronic
regions
26,28,31,66,67 and coding regions.
64,65,68,69
These comparative sequencing studies usually included
several different populations with total sample sizes
between 10 and 494 individuals and populations of
between 4 and 494 individuals.In a recent report,analy-
ses of genes in more than 500 individuals were
described.
70 Contiguous DNA segments in the range of
1.1 kb
68 up to 9.7,
31 24,
32 and about 66 kb
69 were rese-
quenced; in a number of the described studies, the
genomic regions covered were larger than the indicated
segments sequenced,due to the specific genomic organi-
zation of the genes. On average, about 6.4 kb per gene
(range about 1 kb)
68 to about 24 kb
32 were resequenced.
For a more detailed description of these studies,includ-
ing specific data,see reference 39.
Few studies addressed analyses of haplotype/genotype–
phenotype relationships against a background of high
genome sequence diversity in order to test for presence of
genetic risk patterns that might predispose to drug
response and complex disease.
24,29,51The others focused on
evolutionary and population history issues related to the
candidate genes in question.
25-28,30,31,33,34 Some addressed in
particular issues of DNA sequence diversity,complex LD
and haplotype structures,and their potential implications
for disease association studies,
24-26,29,31-33,38 highlighting the
tremendous challenges posed by abundant sequence
diversity for disease association studies.In addition,sub-
stantial gene surveys were performed by application of
variant detection arrays (VDAs).These characterized the
frequency, nature, and pattern of SNPs in 75 candidate
human genes for blood pressure homeostasis and hyper-
tension,
36 and 106 candidate genes relevant to cardiovas-
cular disease,endocrinology,and neuropsychiatry.
37 In a
third,more recent candidate gene survey,nine genes were
scanned by application of denaturing high performance
liquid chromatography (DHPLC).
44 
Abundant DNA sequence diversity in candidate genes
Regarding the amount of genetic variation at the DNA
sequence level, these studies suggest a potentially
remarkable variability in genes,ranging from about one
SNP every 52 bps to about one SNP every 500 bp, at a
mean spacing of one SNP every 215 bp,averaging over
all gene regions included in analysis, which has some-
times been in disproportionate fractions.
39 Summarizing
more specifically studies that have analyzed regulatory,
exonic, and intronic regions in a comparable way, an
average spacing of about one SNP every 166 bp is
observed;including the few studies carried out on coding
regions,an average spacing of about one SNP every 183
bp is obtained.This is in excellent agreement with the
variation data reported in the most comprehensive gene
sequence survey on 313 genes; on average, about one
SNP every 185 bp was detected.
33 Describing candidate
gene variability in absolute numbers,a number of vari-
ants in the range of 6 to 88 per gene was observed, an
average value of about 35 variants given.
25-29,31,32,34,39,64,65,68 If
completely different sets of genes were considered,aver-
age values of about 12 to 15 SNPs per gene (range 0-59)
were obtained.
33,36,37,70 
Overall,this clearly reflects a higher variability than that
reported in the first gene-scanning studies, which sur-
veyed 75 to 106 candidate genes by application of vari-
ation detection arrays;about one SNP every 217 or 346
bp was described.
36,37These estimates of human variation
among individuals also reflect a notable difference to the
previously most frequently cited values of variation
(between an individual’s maternal and paternal
genomes), ie, one sequence difference approximately
every kilobase,
35 and the range being one difference
every 500 to 2000 bases.
36,37,71 Overall,3'UTR,exon-intron
boundaries,5' regulatory,and 5'UTR regions appear to
be more variable than coding regions,ranging from one
SNP every 142 bp (3'UTR) to about one SNP every 294
bp (coding regions).
33
Describing candidate gene variability by allele frequency
spectra (ie,frequencies of the minor allele),about one-
third of the SNPs (30%-38%) were observed only
once.
33,70,72 For less than one-third of the SNPs (28%-
32%),the frequency of the minor allele ranged between
1% and 5%;for about 14% to 17% of the SNPs,the fre-
quency of the minor allele ranged between 5% and 20%;
and for the remaining 11% to 13%,the frequency of the
minor allele ranged between 20% and 50%.
33,70 Sample
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13sizes of analyzed studies ranged from 82 including four
populations
33 to an average of about 290 from one popu-
lation of European descent.
70 Of all SNPs, about 21%
were cosmopolitan,implying that both alleles were pre-
sent in all populations.
33
Regarding the nature of genetic variability,26% to 44%
of all SNPs were found in the coding regions.
33,36,37,70 Of all
the coding SNPs (cSNPs) identified,47% to 56% led to
replacement of an amino acid residue and probably
impact protein function,
33,36,37,70 reflecting a high level of
human protein diversity. The average gene contains
about three to six cSNPs (range 0-17) and about two to
three amino acid exchanges (range 0-15).
33,37,70 With
respect to the functional consequences of coding region
polymorphisms,the most comprehensive survey evalu-
ating 313 genes in 82 individuals of diverse ancestry and
describing a total of 3899 SNPs,
33 provided a classification
of the types of changes based on Grantham values,
73
which are derived from physicochemical considerations.
According to these estimates,about 19% of cSNPs intro-
duced conservative,24% of cSNPs moderately conserv-
ative, 8% moderately radical, and about 4% radical
changes;1.5% of cSNPs introduced a premature termi-
nation codon;and about 1% of all SNPs identified were
within splice sites.
33 Another large-scale gene survey
showed,importantly,that,of the 75 proteins encoded by
the genes that were screened,
36 83% were polymorphic
at the protein level with an average heterozygosity of
17%.These values were considerably greater than clas-
sical protein studies addressing enzyme polymorphisms
in humans,
74 emphasizing the large degree of variation
missed in those earlier studies. These protein-altering
SNPs nevertheless represent only 38% of the total num-
ber of such SNPs expected under the neutral infinite site
models,demonstrating the strong role of natural (puri-
fying) selection (eliminating 62% of replacement SNPs)
75
and functional conservation on human genes.
33,36,37 
Variability and its variability: an intrinsic, gene-specific
characteristic
An important measure to evaluate comparative surveys
of sequence diversity is the nucleotide diversity of human
genes, which is defined by the heterozygosity per
nucleotide site.
76,77 The measures used correct for both
sample size and length of region surveyed. In-depth
analyses showed significant heterogeneity in nucleotide
diversity and functional sequence class.
33,36,37Thus,in cod-
ing sequences,silent SNPs showed 2.5-fold more diver-
sity than replacement SNPs, reflecting functional con-
straint and selection against changes in the protein
sequence.Accordingly,heterogeneity among noncoding
regions was observed:introns are about 50% more vari-
able than 5'UTR or 3'UTR. The greater diversity in
3'UTR than 5'UTR and the relative patterns of noncod-
ing sequence diversity can also be correlated with signif-
icant functional conservation of regulatory sequence.A
cogent argument is that coding sequence changes are not
the only candidates for functional variation and that
SNPs in proximal regulatory regions can have large phe-
notypic impact,too,just as they do in evolution.
36
Taken together, nucleotide diversity shows significant
variation across genes and functional class. Analyses
assuming a neutral allele infinite site model showed that
sequence length explained only 29% of the variation for
cSNPs. Thus, gene-to-gene differences are the most
important of all factors that contribute to such variation.
An intrinsic and characteristic gene-specific diversity
must exist, as illustrated by a 15-fold variation in
nucleotide diversity across genes,with coding segments
being less diverse than noncoding sequences.
36Although
mutation is responsible for creating SNPs,their mainte-
nance probably depends on natural selection on coding
sequences,which in turn is regulated by its precise func-
tional role as well as meiotic recombination.This marked
variability of variability in candidate genes is also illus-
trated by the fact that extremely invariable gene regions
can also occur, with no structural mutations at all, sin-
gletons,or complete absence of any variant in coding or
regulatory regions,even when genes were systematically
resequenced in substantial numbers up to about 200 indi-
viduals.
62,78,79 In particular, an extensive survey by
Halushka et al
36 showed that about 17% of all genes were
invariable at the protein level,which is in agreement with
our extrapolations of a fraction of about 20% of invari-
able genes (Hoehe M et al, unpublished results).This
may be related to certain aspects of yet unknown or par-
ticularly high functional significance among the total
gene pool, and is one of the important questions to be
addressed in the future.Taken together,there is no a pri-
ori way to predict the actual natural variability of a gene;
it must be empirically assessed in appropriately chosen
samples in each case.
An example of the variability of variability in candidate
genes,which may exist even within members of the same
gene family (such as G protein–coupled receptor genes)
State of the art
14or even within members of the same group of receptor
subtypes or genes encoding endogenous receptor ligands,
is given in Figure 3.
80These genes may represent proto-
typic examples of drug targets and their potential vari-
ability,particularly with respect to the fact that more than
50% of the total of 417 receptor targets of pharmaceu-
tical relevance encode G protein–coupled receptors.
4
For instance, in the human µ-opioid receptor gene
(OPRM1) (Figure 3a),a target for morphine,the classi-
cal pain killer in contemporary medicine and substance
of abuse,a total of 43 variants have been identified within
6.7 kb in 250 European- and African-Americans.
29
Clearly,the 5' regulatory and 5'UTR regions (one SNP
every 99 bp and 73 bp, respectively) and the critical
regions in intron 2 (one SNP every 110 bp) were much
more variable than the coding exon (one SNP every 267
bp) and other intronic regions.Five of the six SNPs in the
coding region clearly affected the encoded protein;two
of those (which were relatively frequent) were located in
the N-terminal,one in the third transmembrane domain,
and two in the third cytoplasmic loop;all were shown to
induce functional alterations.
82,83
A different picture can be observed in the human β1-
adrenergic receptor gene (ADRB1), about 250 bp 5'
flanking and 1434 bp coding regions of which were
scanned in about 80 individuals of European descent.
81A
total of 20 variants were observed, 17 of which were
located in the coding region.Two variants in the N-ter-
minal and five in the C-terminal caused an amino acid
exchange (Figure 3b),which amounted to a much higher
calculated density of SNPs in the coding region, about
one SNP every 84 bp.The human β2-adrenergic receptor
gene (ADRB2),about 3 kb,has been resequenced in a
total of several hundred individuals
70;15 variants,8 in the
5' regulatory region including the leader peptide and 7 in
the coding region,have been identified,at a roughly com-
parable spacing of one SNP every 175 to 200 bp.
55,70The
mutation in the leader peptide and three coding SNPs,
two of which were located in the N-terminal,were found
to be functionally significant
57-59; by far the majority of
variants were highly frequent.
The human CB1 cannabinoid receptor gene (CNR1),
another member of the G protein–coupled receptor gene
family,was found to be remarkably invariable within and
between species,
62 when analyzing a total of about 200
individuals including European- and African-Americans
as well as Europeans exhibiting extreme responses to
cannabis use;only two silent substitutions were observed
within about 1500 bp coding region. Similarly, notable
invariability was observed in the coding regions of two
chemokine receptor gene subtypes (Ohl et al, unpub-
lished data).Finally,completely invariable coding exons
and few SNPs in intronic regions were found in the
human promelanin concentrating hormone gene
(PMCH), a neuropeptide and endogenous ligand
(Hoehe et al,unpublished data).
Taken together,current approaches to describe,evaluate,
and compare genetic variation in candidate genes remain
in many aspects grossly insufficient and merely descrip-
tive.They rely predominantly on the determination of
frequency patterns and average values that describe and
distinguish variability per se, as well as different cate-
gories of variants or functional gene sequence classes.
These approaches allow,however,specific predictions of
the nature and distribution of SNPs in the estimated 30
000 human genes, ie, in a study about 300-fold larger.
Consequently,they may also allow extrapolations on the
nature and amount of variability in potential drug targets.
On the other hand, without knowledge of the specific
functional variation in the genes underlying given
nucleotide diversity, which will have to be based upon
characterization of entire,individually different forms of
the gene and its product, the implications of the vari-
ability of candidate genes may hardly be evaluated and
compared.The previous approaches to the characteriza-
tion of genetic variation are in essence single SNP ori-
ented.They do not therefore allow any conclusions on
variation in its context,as represented by given haplotype
structures of the gene,the very basis for functional eval-
uation.
A multiplicity of gene-based haplotypes
Similar observations were made for haplotypes.
Potentially large numbers of haplotypes per gene as well
as a notable variability of these numbers were observed.
Absolute numbers of haplotypes described to date range
from 2 to 88
24-29,31-34,39,58,59 up to 140
70;average numbers are
about 14 haplotypes per gene (range 2-53) in 82 individ-
uals from four populations in the most comprehensive
survey,
33 8 haplotypes per gene (range 4-15) in about 40
to 60 individuals from one population of European
descent,
46 70 haplotypes per gene (range 16-140) in an
average of about 309 individuals (range 141-469) from
one population of European descent
70;the average num-
bers of SNPs per gene in these studies were 12,
46 12.5,
33
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Figure 3. Polymorphic spectra of candidate genes.
80 The genomic reference sequences are presented as baseline, exonic sequences as gray or white
(untranslated regions [UTRs]) bars; sequences were drawn to scale, which is indicated. All gene variants are specified by nucleotide varia-
tions (substitutions, insertions, and deletions) according to the mutation nomenclature. Candidate genes had been subjected to systematic
comparative sequencing. A. The human µ-opioid receptor gene (OPRM1), about 6.7 kb, in 250 individuals.
29 B. The human β1-adrenergic
receptor gene (ADRB1), about 2 kb, in about 80 individuals.
81 C. The human β2-adrenergic receptor gene (ADRB2), about 3 kb, in 515 indi-
viduals.
70 D. The human CB1 cannabinoid receptor gene (CNR1), about 1.6 kb, in about 200 individuals.
62 E. The human promelanin con-
centrating hormone gene (PMCH), about 1.2 kb, in 141 individuals. 
Reproduced from reference 80: Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the impor-
tance of haplotypes and implications for pharmacogenomics. Curr Pharm Biotechnol. 2003;4:351-378. Copyright © 2003, Bentham Science Publishers.and 31.
70 Thus, the number of haplotypes appears to
increase dramatically with the number of individuals and
SNPs analyzed,
38 and the upper end is not yet in sight;
sequenced or scanned
44 segments ranged in average from
2.3 kb
33 to 4.9 kb
70 to 15 kb per gene.
46 
At the other end of the spectrum is the resolution into
haplotypes as described in the analysis of the LPL gene,
an important potential genetic risk factor for cardiovas-
cular disease;about 9.7 kb of contiguous gene sequence
including six of nine exons and significant fractions of
intronic sequence were systematically compared in 71
individuals from three populations.
31 Eighty-eight distinct
haplotypes were determined from 88 segregating sites;
only three of the 88 haplotypes were detectable in all
three populations and 21, 25, and 35 haplotypes were
found unique to one of the three populations, respec-
tively.
38Taken together,in analogy to genetic variation at
the DNA sequence level, a notable variability of vari-
ability can be observed.
The relationship between the number of variants and
number of underlying haplotypes seems to vary signifi-
cantly,
33,39,70 with the number of haplotypes being similar,
much larger (up to eightfold)
25,27,29,33,65,70 or significantly
smaller
32-34,64 than the number of SNPs. On average
though,a linear relationship between the number of indi-
vidual SNPs within a gene and the number of resulting
haplotypes was observed in the most comprehensive sur-
vey.
33 In addition, a slightly higher average number of
haplotypes per gene (by a factor of 1.1) than number of
SNPs was observed.
33The fact that the number of haplo-
types is greater than the number of SNPs indicates that
some degree of recombination and recurrent mutation
may have occurred within these genes,
33 which has also
been emphasized in other studies.
25-27,34,38 
These analyses demonstrate that the decomposition of
genes into different haplotypes,the so-called gene-based
haplotype diversity,is remarkable.In fact,many genes do
not have one predominant haplotype at all,and the total
fraction of rare haplotypes contributing to the picture
may be significant.Specifically,in the largest survey per-
formed to date,
33 no single haplotype showed a frequency
≥50% in 35% of the genes.The most common haplotypes
described ranged in frequency between 12% and
48%
24,25,27,29,34,46,70;overall,the number of common haplo-
types with frequencies >5% was found to be in the range
of two to seven and to account for 43% to 97% of all
haplotypes.
24,25,27,29,34,46,70 For instance, 52 different haplo-
types in a group of 172 individuals including cases and
controls were predicted in the OPRM1 study
29;of those,
three haplotypes ranging in frequencies between 7% and
39% accounted for 60% of all haplotypes and nine hap-
lotypes ranging in frequencies between 2% and 39%
accounted for 80% of all haploypes (Figure 4a).
Referring to the human β2-adrenergic receptor gene,four
different haplotypes at frequencies ≥5% (range 7% to
20%) constitute 51% of all haplotypes (Figure 4b);con-
sidering the eight haplotypes within a frequency range of
2% to 20%,these constitute only 62% of all haplotypes
of this gene.
It is noteworthy that in the highest resolution compara-
tive sequencing study performed to date on samples of
234 to 469 individuals,four to six common haplotypes at
frequencies in the range of 5% to 20% were found to
account for 51% to 57% of all haplotypes.
70The relative
proportion of rare haplotypes (<1%) observed amounted
to 7% to 49%,
25,27,29,70 and ranged in absolute numbers
from 14 to >100.
25,27,29,70 Specifically referring to the exam-
ple of OPRM1 haplotypes,43 different rare haplotypes
accounted for 20% of all haplotypes (Figure 4a). It is
important to note in this context that potentially impor-
tant risk haplotypes were included in this class of rare
haplotypes,whereas the common haplotypes occurred at
similar frequencies in cases and controls.
29,39 Referring to
the β2-adrenergic receptor gene,for which significantly
more than 100 haplotypes have been inferred to date,
70
rare haplotypes accounted for 38% of all haplotypes,
haplotypes <5% in fact for 49% of all haplotypes
67
(Figure 4b).A large number of rare and population-spe-
cific haplotypes have generally been observed in the
majority of studies.
24-29,31-34,39,64,65At the extreme,the haplo-
type profile of a gene may even be characterized by
groups of relatively infrequent haplotypes (Figure 4c),
where literally no sequence haplotype at a frequency
>4% existed;rather,four different groups that contain a
total of 64 different haplotypes at frequencies ranging
between 3% and 4%,2% and 3%,1% and 2%,and <1%
may,somewhat arbitrarily,be distinguished.On the other
hand,taking haplotype frequencies into consideration,
cosmopolitan haplotypes accounted for nearly 82% of
the total haplotypes observed,whereas population-spe-
cific haplotypes accounted for only about 8%.
33
The concept of a gene revisited
There are multiple haplotypes that account for a signifi-
cant fraction of human genomic variability. The initial
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17results clearly challenge the concept of the gene,and par-
ticularly the view that there exists one predominant form
of a gene as the wild-type and various rare or mutant
forms.This may well indicate the beginning of the end of
Mendel’s world
10 and its view of the amount,nature,pat-
tern, and structure of genetic variation.The two-allele
concept of the gene may for the time being have been
nothing but the extreme and visible end of an entire spec-
trum,given the (until recently) limited access to genetic
variation.Studies to come that will analyze continuously
increasing numbers of individuals and increasingly larger,
eventually complete gene regions (which may well extend
up to about 100 kb and more) are likely to generate even
more complex results.In brief,the concept of a gene may
have to be revised completely
10,29,33:the gene as a concrete
molecular substrate does not exist.Genes rather appear
to exist as a spectrum of different forms; the gene will
have to be redefined as the sum of its haplotypes.The def-
inition of a gene will have to include the positions,popu-
lation specificities,and characterization of its variants,and
a precise description of its haplotype structures.It is obvi-
ous that the next level of description (and the first step to
reduce haplotype complexity) will be the assignment of
the sequence haplotypes to the protein isoforms they con-
stitute.Needless to say that such a revision of the concept
of the gene will have profound consequences on the analy-
sis and classification of gene function,as well as its role as
a drug target.
State of the art
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Figure 4. Distribution of haplotype frequencies. Each color-coded segment represents proportionately the frequency (in percent) of one specific hap-
lotype, the corresponding haplotype numbers are given in the box; the red-colored segments contain the fraction of haplotypes with a fre-
quency <1%. A. Haplotype frequencies of the human µ-opioid receptor gene (OPRM1), for corresponding numbers see reference 29. B.
Haplotype frequencies of the human β2-adrenergic receptor gene; numbers in the box refer to a table of haplotypes predicted for 237 indi-
viduals (data not shown). C. Haplotype frequencies of the bradykinin receptor B2 gene (BDKRB2); numbers in the box refer to a table of hap-
lotypes predicted for 234 individuals (data not shown). In this case, each color-coded major segment does not refer to a specific haplotype,
but includes a number of haplotypes within a specific, defined frequency range; this is indicated by the subdivisions into multiple smaller, spe-
cific segments, each of which corresponds to one specific haplotype within the segment. 
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Knowledge on genetic variation and haplotype struc-
tures: an essential prerequisite for drug target discovery
and optimization
The approaches and research data outlined above raise
two major issues.First,how do the different approaches
to candidate gene analysis apply to the various aspects of
pharmacogenomics? Second,which conclusions and con-
sequences should be drawn, taking into account the
recent results demonstrating potentially abundant can-
didate gene sequence diversity and complex haplotype
structures? 
With respect to the first issue,all the entire individually
variable candidate gene sequences corresponding to the
gene-based functional haplotypes described earlier are
the immediate correlates of pharmaceutical relevance as
(i) the potential molecular correlates of the disease genes
and naturally occurring different forms of the genes,since
they provide the immediate links to gene function(s) and
dysfunction;and (ii) the direct objects of in vitro expres-
sion and units of functional characterization and there-
fore in vitro test systems for drug action.It is these gene-
based functional haplotypes and their characteristics that
serve as the reference substrates for target evaluation
and prioritization.Because disease genes also mark func-
tional pathways,they may serve as reference molecules
for other related molecules in the affected network,
which may represent more suitable drug targets with
regard to their molecular properties and genetic vari-
ability pattern.
With respect to the second issue,one major consequence
to be drawn is to establish as an essential requirement of
the systematic and comprehensive analysis of the entire
individual gene sequences encoding the drug targets in
appropriately chosen samples. It will be mandatory to
determine the entire polymorphic spectra of the genes,
as well as the haplotype structures underlying them.A
second critical analytical task in this context will be to
evaluate to what extent potentially given complexity can
be reduced to functionally distinct haplotype classes
and/or distinct protein isoforms.In-depth knowledge on
the genetic variability of a drug target under considera-
tion,especially the spectrum and frequencies of under-
lying haplotype structures in populations,
84 will have to
become an indispensable prerequisite for drug target
evaluation,characterization,and prioritization.Needless
to say these requirements refer to both the specific drug
targets under consideration and the genes involved in
drug metabolism and transport.
There is currently no a priori way of predicting the spe-
cific genetic variability in a drug target or any other gene
of pharmaceutical relevance,given its stochastic nature;
each gene must be rigorously subjected to systematic
comparative sequence and haplotype analysis in popula-
tions. Extrapolating from the body of data described
above,about two to seven different haplotypes that occur
most frequently (at frequencies of the minor allele >5%)
may be expected on average.This implies that the most
frequent haplotypes amount to fractions of 16% to >50%
of all haplotypes,constituting altogether about 51% to
96% of the total of haplotypes.
29,33,46,70 Moreover,the num-
bers of rare haplotypes (frequencies of the minor allele
<1%) may potentially be substantial,as outlined above.
However,diversity at the sequence and haplotype level
does not necessarily imply diversity at the protein level.
Thus,the assignment of individual sequence haplotypes
to protein isoforms will be one first,critical step towards
the evaluation of the implications of given candidate
gene variability. Hardly any data have been presented
regarding the relationships between sequence haplotypes
and protein isoforms,with the exception of the work on
APOE sequence haplotypes by Fullerton et al.
25These
authors demonstrated convergence of 31 different
sequence haplotypes onto three different protein iso-
forms.Beyond that,diversity at the protein level may not
necessarily imply diversity at the functional level,an issue
whose clarification will be left to the more distant future.
Rare haplotypes,which per se apparently do not repre-
sent particularly favorable drug targets,may nevertheless
require particular attention as potential mediators of
severe side effects and may constitute significant frac-
tions of individual gene sequences resulting in the same
protein isoform
25 or share a common pattern conferring
risk.
29 Finally, as outlined earlier, any extreme may be
possible:this may include,at the one end of the spectrum,
completely invariable genes that may amount to about
20% of all genes and, at the other end, highly decom-
posed genes with frequencies of numerous sequence hap-
lotypes not exceeding 4%,for instance.
Obviously,a drug target is the more attractive if it has a
low variability and decomposition into different haplo-
type(s) (classes) and protein isoforms.In this context,the
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19modern version of a blockbuster drug target in the
postgenome age of genetic variation would be an invari-
able gene.The pharmaceutically most attractive compo-
nent of a proposed catalogue of all haplotypes of all
genes as the ultimate biomedical resource would prob-
ably be the specific fraction containing the most invari-
able genes.In reality though,we may have to concentrate
on manageable variability,ie,scenarios where variability
is limited or the functional implications are clearly defin-
able.If a drug has not been tailored a priori to the target
in its variable,naturally occurring forms,incompatibili-
ties,ineffectiveness,and adverse side effects will become
apparent sooner or later.The molecular truth will even-
tually take its toll on both individuals and the pharma-
ceutical industry.
Any developments that are driven by the vision of a per-
sonalized medicine
11-14 will have to be based on knowl-
edge of the molecular diversity of potential drug targets
and,generally,of any genes involved in drug action and
metabolism.
9,85,86 This information will be essential for
decision-making processes. It will also be valuable in
guiding in vitro screens and their specific experimental
design.It will allow an extrapolation of drug response in
population segments,as well as a correlation of in vitro
and in vivo responsiveness (in conjunction with infor-
mation on the genetic makeup of drug-metabolizing
enzymes and competing,homologous targets).The inte-
gration of knowledge on human genetic variation into all
phases of drug development and application will be one
of the pharmaceutical industry’s major future tasks.Last
but not least,what does the evidence for gene decompo-
sition into multiple forms tell us about the prospects for
an individualized medicine?
11-14,87The fact that individual
sequence differences exist does not mean that tailoring
drugs to each individual is possible or feasible.Given the
remarkable genetic diversity and its challenges,this vision
may seem somewhat too bold and unrealistic at this
stage. However, a focus on population stratification as
well as avoidance of serious harm through attention to
rare profiles may merit very serious consideration.
88,89 
Gene-based haplotype analysis and diagnostic validity
Gene-based haplotypes seem appropriate as complex
genetic markers,
48 if extraction of these diagnostic mark-
ers is based on systematic analysis of underlying LD and
haplotype structures in the populations.The number of
SNPs necessary to validly represent those structures may
well range between one or a few
48 and many (Ott,per-
sonal communication). As pointed out, randomly
selected SNPs in and around the gene, even frequent
ones, may not be able to distinguish between different
underlying haplotypes and, importantly, not between
high- and low-risk haplotypes.Thus,the selection and use
of SNPs as diagnostic markers for the prediction of drug
response and disease risk will have to be subjected to rig-
orous criteria.Finally,it is interesting to note that even
for mendelian types of disease causation,numerous alle-
les may have to be taken into consideration.
10,90
An ultimate resource for drug discovery
In view of the tens of thousands of genes existing in the
human genome, many of which may not yet be accessi-
ble to even the most advanced approaches to predict or
annotate function, the future, bold alternative to any
strategy of candidate gene selection and testing will be
the simultaneous analysis of all functional haplotypes of
all genes against phenotype.This may, at some point,
turn out to be even more efficient, if the appropriate
technologies are at hand,than the extensive approaches
to hypothesis generation and testing described above.
Such an approach would represent the haplotype-based
version of the candidate gene association mapping
approach proposed by Risch and Merikangas
91 as the
future of the genetics of complex disease, which was
originally based upon a two-allele concept of the
gene,
90,91 as was the catalogue of common SNPs envis-
aged by Lander.
92 In such a catalogue of all haplotypes,
each gene would be represented by the entire spectrum
of individually different forms of the gene,both the cos-
mopolitan
33 and the population-specific ones.Such a cat-
alogue would also include annotations of all individually
variable sites including changes in regulatory,exonic,and
intronic sequences (function-tagged sites)
6 and,as far as
possible, annotations of the entire haplotypes as func-
tional units. In addition, a classification of these haplo-
types with respect to their functional similarity would
seem a most valuable asset to such a resource.To what
extent the necessary functional annotations will have to
be achieved in silico or in vitro, remains open.
Additional information of potentially great value would
be the fraction of highly invariable genes.These would
represent that kind of drug targets that most closely
would fulfil the criteria for blockbuster targets, as out-
lined above.
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The multiplicity of individual gene forms and their
relation to gene function and phenotype: challenges
and first solutions
These initial comparative sequencing studies have demon-
strated that numerous individually different forms of the
gene may exist.Eventually,at the ultimate level of resolu-
tion including increasingly large regions of analysis and
increasingly large numbers of individuals,every haplotype
may become unique.
38 It remains unknown whether the
number of different haplotypes may,at some point,reach
a level of saturation,or whether their number will increase
infinitely.The molecular truth emerges:the fact that mul-
tiallelism may be the rule rather than the exception.
10,90
Referring to the gene variability data presented above,the
number of different haplotypes may become unfeasibly
large,
29,38,90 so that the power is not sufficient to detect an
association of the disease phenotype or drug response with
any single haplotype.Thus,this allelic complexity imposes
tremendous challenges on the establishment of haplo-
type/genotype–phenotype relationships.
29,38The following
key questions arise:how should genotype–phenotype rela-
tionships be analyzed against a background of high nat-
ural genome sequence diversity? How should the impor-
tant variants be filtered from the unimportant ones?
Approaches to reduce this complexity and condense infor-
mation on genetic variation will be required.
Various approaches to the grouping,or classification,of
haplotypes have been suggested.One major approach to
reduce complexity has been the grouping of haplotypes
by evolutionary relatedness as the basis for association
studies;this approach has been described in detail in a
previous review.
93The historical information from differ-
ent haplotypes is combined to construct a cladogram that
estimates how the different haplotypes are evolutionar-
ily related.This allows localization of functional muta-
tional changes in the haplotype network by identification
of phenotypic contrasts between sister clades.The use of
an evolutionary tree as a statistical design may become
difficult when the evolutionary history of a population
may have been influenced by various forces,such as high
rates of recombination,multiple mutations to high sus-
ceptibility alleles,and others.
29The reconstruction of the
specific evolutionary processes in general,and the con-
struction of evolutionary trees in the presence of recom-
bination events in particular,may become extremely dif-
ficult—if not unfeasible—in most complex genetic dis-
ease studies.
Another approach could be the extraction of the most
frequent haplotypes (>5%), which constitute—on the
basis of preliminary results—about 51% to >90% of all
haplotypes,
46,70 and subsequent evaluation,whether one
of these haplotypes may occur significantly more fre-
quently in cases than controls.This approach is based on
the a priori assumption that common haplotypes play a
major role in the genetics of common disease,
23,94 which
is a highly controversial topic.
94-97This approach will,how-
ever,not capture a genetic risk scenario that involves rare
mutations
65-68 or rare haplotypes.
29A number of examples
have demonstrated that rare variants and/or haplotypes
may confer genetic susceptibility to complex disease,
whereas the common haplotypes did not allow distinc-
tion of cases and controls in some of these examples.
39,65-68
Thus,a focus on the groups of common haplotypes from
the outset does not appear to be a sound solution.
Conceptually,another approach to cope with the multi-
plicity of haplotypes could be envisioned,which seems
the most promising and reasonable:the classification of
haplotypes into functionally related (ideally functionally
equivalent) haplotypes based on sequence–structure–
function similarity.
29 Needless to say that this will by no
means be less challenging than,for instance,the (re)con-
struction of evolutionary trees described above.
However,such an approach would not rely on the recon-
struction of evolutionary history with its many unknowns,
but focus on the “here and now”; the given sequence
would not be considered as an end point of history,but
as the information that determines structure and func-
tion of the protein.Such an approach would seem more
generally applicable.
Initial approaches have been explored,
29 applying a step-
wise classification process, for example, a hierarchical
cluster procedure. Haplotypes are grouped into ever
more inclusive classes,until only one final cluster is left.
This approach relies on the assumption that the existence
of functionally different classes would be likely,if at least
one class included haplotypes from cases more (or less)
frequently than controls.If this is the case,the haplotypes
in the different clusters can be inspected for consensus
patterns.The patterns observed more frequently among
individuals with the disease could be interpreted as
genetic risk pattern(s).
Apart from these first attempts, the reduction of com-
plexity through the grouping of functionally equivalent
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theless to represent the ultimate approach,which would
provide the basis to immediately establish the links
between genetic variation,gene function,and dysfunc-
tion.Major challenges will include the development of
valid similarity measures for classification procedures
that incorporate properties that determine sequence–
structure–function similarities,such as physicochemical
properties.Altogether,the development of approaches
to reduce haplotype—and genotype—complexity
through classification will be critical to the future of the
genetics of complex disease and all aspects of pharma-
cogenomics as outlined above.
Genetic variation and its functional implications:
the units of analysis 
As indicated above,the analyses of the functional impli-
cations of candidate gene variation have been performed
almost entirely with focus on single SNPs, taken out of
context.Thus,the conclusions drawn may hardly be valid
for the majority of naturally occurring individual gene
sequences and the functions they encode.This means that
the unit of functional analysis will have to change:from the
previously standard single mutation analysis in vitro to the
functional analysis of entire individual gene sequences or
the gene-based functional haplotypes (sequence haplo-
types) of a gene.The challenges are obvious, given the
potentially abundant variations in all,regulatory,coding
and intronic sequences.First paradigmatic results from a
functional sequence haplotype analysis in the human β2-
adrenergic receptor gene show that the effects of the var-
ious SNP combinations are different from those previously
obtained with individual SNPs taken out of context of a
verified haplotype.These first results clearly support the
importance of studying SNPs in vitro within the context of
a validated haplotype.
24
In this example,the bronchodilator responses in vivo to
β2-agonist were significantly related to haplotype pairs,
but not to any individual SNP.Expression of the haplo-
types associated with divergent responsiveness clearly
demonstrated that receptor mRNA levels and receptor
density in cells transfected with the haplotype associated
with the greater physiological response were about 50%
greater than those transfected with the lower-response
haplotype.
24These results indicated that the unique inter-
actions of multiple SNPs within a haplotype can ulti-
mately affect biological and therapeutic phenotype,and
that individual SNPs may have poor predictive power as
pharmacogenetic loci.The authors conclude from their
results that it is likely that the biological phenotype is
directed by an interaction involving transcription,trans-
lation,and protein processing,which ultimately defines
the effect of these haplotypes.
24The challenges of ana-
lyzing and interpreting given genetic variation at all lev-
els are daunting and,obviously,the true challenges will
be biological.Nevertheless,the initial steps toward solu-
tions have been taken.
Gene variability, the genetics of complex traits, and
future approaches to the analysis of complex systems 
The analysis of individual candidate genes constitutes an
essential analytical entity,which is part of a bigger pic-
ture. The majority of diseases and individual drug
response are prototypic complex traits and may involve
interactions of several or multiple genes or entire gene
networks with the environment.
98The complexity of the
trait also arises from the fact that genetic and environ-
mental factors may interact with each other in unpre-
dictable ways,such that the association between the phe-
notype and any single genetic factor may be
imperceptible.
98,99 Nonlinear interactions, including
gene–environment interactions,mean that the expression
of the phenotype may not be accurately predicted from
knowledge of the individual effects of each of the com-
ponent factors considered alone, no matter how well
understood the separate components may be.
100 A full
catalogue of the genetic architecture of complex pheno-
types consists of a description of all the genetic and envi-
ronmental factors that affect the phenotype,along with
the magnitude of their individual effects and the inter-
actions among the factors.Clearly,this represents the par-
ticular challenge, underscores the importance of the
analysis of gene–gene–environment interactions, and
implies that potentially many different models of inter-
actions will have to be explored.
In this context,individual variation in drug response may
involve any of the gene networks that are part of the
complex interplay between specific disease-associated
factors,pharmacokinetics,and pharmacodynamics.
9,85-87,99
These may include any of the functional pathways
involved in the specific pathophysiology of the disease.
Nonresponse may, for instance, be due to genetic het-
erogeneity in disease etiology.In this case,the drug may
not target the specific causative mechanisms active in the
State of the art
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87 Moreover, the gene encoding the specific
drug target represents the first component of an entire
downstream pathway that controls signal transduction
and elicits the cellular effects.Thus,genetic variation in
any of the genes regulating this pathway may cause vari-
ation in drug response.Furthermore,numerous genes or
gene families are involved in drug transport and drug
metabolism,such as the genes encoding the phase I and
phase II enzymes,which are expressed in the liver.
9,12,85-87,99
In addition, environmental factors, such as nutrition,
exercise,access to substances of abuse,etc,may influence
drug response.
In the future,progress in the understanding of the mole-
cular bases of disease and drug response is expected to
come especially from advances in functional genomics as
the basis for whole complex systems analysis. These
advances will be based on the increasing elucidation of
the function of all genes involved in all pathways consti-
tuting the relevant process.In this new approach to bio-
logical research,the same type of analyses,which are typ-
ically used to try to understand the function of single
genes,are carried out on most or all genes of the organ-
ism.Enormous amounts of information on the networks
of biological processes are being generated,leading to
the establishment of models of specific functional net-
works.Apart from deriving many novel candidate genes
and drug targets of interest,this may provide yet another
approach to group multiple variants in genes,in which
according to functional context,the model is used as a
template for classification and functional interpretation
of a spectrum of gene variants.Thus,systems analysis can
be extended to pose the question of whether a specific
metabolic pathway involving many genes of variable
variability could be involved in a specific phenotype or
disease.In such an analysis,mutations in any of the genes
of the pathway, each of which occurs at too low a fre-
quency to be significant in itself, could be pooled to
increase the overall significance. The power of this
approach to establish genotype–phenotype correlations
will become even greater once the information on vari-
ants can be combined into functional units of increasing
complexity and once these biological processes can be
comprehensively modeled by systems analysis.
In the future, we can also hope to gain considerable
power in the establishment of the more complex geno-
type–phenotype relationships by the modeling of the pre-
dicted effects of any sequence variant or combination of
sequence variants,taking into account cis effects (all vari-
ants affecting the function of a specific gene on a specific
chromosome in a haplotype),trans effects (complemen-
tation between the two copies of each gene on auto-
somes), as well as gene–gene and gene–environment
interactions.It is highly likely that the establishment of
quantitative models of all of these effects and interac-
tions will be essential to derive many of the more com-
plex genotype–phenotype relationships,and to ultimately
understand many of the complex biological and disease
processes. Even if biology may be too complex to be
understood in the classical sense,the best we can possi-
bly hope for is to establish models of these processes that
correctly predict all the parameters we can assess.Such
systems will be a key step in being able to use the enor-
mous amount of knowledge being generated to improve
diagnosis and therapy,and ultimately guide therapy in an
individual patient.Thus,hopes are high that these devel-
opments will have a major impact on medicine and pre-
pare the ground for the future of an optimized,patient-
oriented therapy. ❏
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Variación genética y farmacogenómica: 
conceptos, hechos y desafíos
El análisis de la variación genética en genes candi-
datos es un tema de gran importancia en la farma-
cogenómica. Los abordajes específicos que se adop-
ten tendrán un impacto crítico en la identificación
exitosa de genes enfermos, en los correlatos mole-
culares de la respuesta a fármacos y en el estableci-
miento de relaciones significativas entre variantes
genéticas y fenotipos de importancia biomédica y
farmacéutica en general. Este artículo describe el
contexto histórico y desarrolla diferentes opciones
sobre el análisis de un gen candidato, lo que refleja
las diferentes etapas en la investigación del genoma
humano. Sólo recientemente ha sido posible anali-
zar sistemáticamente la variación genética con el
máximo nivel de resolución, es decir, la secuencia del
ADN. En este contexto, considerando que sólo
recientemente se ha reconocido la importancia de
aproximaciones basadas en haplotipos para el análi-
sis de genes candidatos, resulta esencial la determi-
nación de combinaciones específicas de variantes
para cada una de las dos sequencias de un gen que
determinan el haplotipo. Se entregará un resumen
actualizado de la información más precisa acerca de
la cantidad, naturaleza y estructura de la variación
genética de los genes candidatos. Esta información
es una prueba de la diversidad de secuencias de
genes y de haplotipos existentes. Pueden existir
numerosas formas individualmente diferentes de un
gen. Esto representa grandes desafíos para el análi-
sis de las relaciones entre la variación genética, la
función del gen y el fenotipo. Hay soluciones preli-
minares que parecen estar al alcance de la mano.
Actualmente resultan evidentes las implicancias para
la farmacogenómica y la medicina “personalizada”
de la variación que ocurre en forma natural. Futuras
aproximaciones para la identificación, evaluación y
prioridad de fármacos blanco, para la optimización
de ensayos clínicos y para el desarrollo de terapias
eficientes deben estar basadas en un conocimiento
en profundidad de la variación de genes candidatos
como un prerequisito esencial.
Variation génétique et pharmacogénomique :
concepts, faits et défis
L’analyse de la variation génétique des gènes can-
didats est un problème d’une importance capitale en
pharmacogénomique. Les approches spécifiques sui-
vies auront un impact crucial pour le succès de l’iden-
tification des gènes responsables d’une maladie, les
corrélats moléculaires de la réponse au médicament
et l’établissement de relations significatives entre les
variantes génétiques et les phénotypes ayant une
importance biomédicale et pharmaceutique en
général. Sur un arrière-fond historique, cet article
distingue différentes approches de l’analyse du gène
candidat, reflétant diverses étapes de la recherche
sur le génome humain. Ce n’est que récemment qu’il
est devenu possible d’analyser systématiquement la
variation génétique au niveau ultime de la résolu-
tion, c’est-à-dire la séquence ADN. Dans ce contexte,
l’importance des approches de l’analyse du gène can-
didat basées sur l’haplotype a enfin été reconnue ; il
est essentiel de déterminer les combinaisons spéci-
fiques des variantes pour chacune des deux
séquences géniques, que l’on définit comme un
haplotype. Nous donnerons un résumé à jour de
telles données de résolution maximale sur la quan-
tité, la nature et la structure de la variation géné-
tique des gènes candidats. Ces données démontrent
une grande diversité dans les séquences géniques et
les haplotypes. Il peut exister de nombreuses formes
individuelles différentes d’un gène. Ceci représente
un défi majeur pour l’analyse des relations entre
variation génétique, fonction du gène et phénotype.
Des solutions préliminaires semblent être à notre
portée. Les implications des variations survenant
spontanément sont maintenant évidentes pour la
pharmacogénomique et la médecine « personnali-
sée ». De futures approches pour l’identification,
l’évaluation et l’établissement de la liste des priori-
tés des cibles médicamenteuses, l’optimisation des
essais cliniques et le développement de traitements
efficaces doivent être basées sur une connaissance
approfondie des variations des gènes candidats
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